MedTrace Logo

Influence of Anesthetics on Clinical Outcome in Mitral and Aortic Valve Replacement in Adults

NCT05696509 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-01-25

No results posted yet for this study

Summary

Abstract Anaesthetic support for cardiac surgery significantly influences the course of the intraoperative period and the success of the postoperative period. Total intravenous anaesthesia and inhalation anaesthesia are the traditional methods of anaesthesia in cardiac surgery. However, there are few studies assessing the effectiveness of surgical aggression protection in cardiac surgery.

Objectives: To study the effect of anesthetics on clinical outcome after mitral and aortic valve replacement in adults.

Methods. The data of 75 patients operated in the Cardiosurgery Department of the Medical Center Hospital of the Presidential Administration of the Republic of Kazakhstan were included in the study. All patients underwent mitral, aortic valve replacement/plasty under cardiopulmonary bypass (CPB) conditions.

All patients were divided into 3 groups according to the type of anaesthesia: the first (1) group patients anaesthetised with propofol (P), the second group with sevoflurane (S), and the last one is with isoflurane (I).

To maintain anaesthesia in Group 1 propofol was used as anaesthetic in a dose of 6 mg/kg/h intravenously on perfusion. In Group 2 the anaesthetic used was sevoflurane in a dose of 1.7-1.9 MAC. Group 3 used isoflurane in the dose of 1.1-1.2 MAC as anaesthetic. Statistical analysis was done by the method of single factor analysis of variance and Kruskal Wallis criterion.

Conditions

  • Mitral Valve Insufficiency
  • Aortic Valve Insufficiency

Interventions

DRUG

Propofol

To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor.

DRUG

Isoflurane

Isoflurane was used as an anaesthetic in a dose of - 1.1-1.2 MAC

DRUG

Sevoflurane

sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC

Sponsors & Collaborators

  • Astana Medical University

    lead OTHER

Principal Investigators

  • Alibek Kh Mustafin, Professor · Astana Medical University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-03
Primary Completion
2022-10-13
Completion
2022-10-16

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05696509 on ClinicalTrials.gov